BioCardia, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.3 million, a decrease from a net loss of $2.7 million in the same period of the previous year. The company's total revenue for the quarter remained modest, with no significant figures disclosed, reflecting its ongoing status as a clinical-stage company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The decrease in net loss was attributed to reduced research and development expenses, which fell to approximately $1.2 million from $1.5 million, primarily due to the closeout of the CardiAMP Heart Failure Trial.
In terms of operational metrics, BioCardia's total costs and expenses decreased to $2.3 million from $2.7 million year-over-year. Selling, general and administrative expenses also saw a decline, dropping to approximately $1.0 million from $1.2 million, largely due to lower professional service fees. The company’s cash and cash equivalents stood at $951,000 as of March 31, 2026, down from $2.5 million at the end of 2025, raising concerns about its liquidity and ability to fund operations beyond June 2026 without additional capital.
Strategically, BioCardia is advancing its CardiAMP autologous cell therapy platform, which is currently in clinical trials for ischemic heart failure and chronic myocardial ischemia. The company is also pursuing regulatory approvals in both the United States and Japan, with recent positive feedback from the FDA regarding the CardiAMP Cell Therapy System. Additionally, BioCardia is exploring the market release of its Helix transendocardial delivery system, which is designed for minimally invasive therapeutic delivery to the heart.
The company has indicated that it plans to raise additional capital to support its ongoing operations and development activities. BioCardia's management has expressed that the current cash reserves are insufficient to meet planned expenditures, and they are considering various funding options, including equity and debt financing. The outlook remains cautious, with management acknowledging the substantial doubt about the company's ability to continue as a going concern without securing further funding. The financial statements do not include adjustments that might result from this uncertainty, highlighting the critical need for additional capital to sustain operations and advance clinical programs.
About BioCardia, Inc.
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, including ischemic heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. Its core products include the CardiAMP autologous cell therapy system and CardiALLO allogeneic mesenchymal stem cell therapies, delivered via the proprietary Helix biotherapeutic delivery platform. BioCardia targets specialist cardiologists and medical centers, leveraging patented technologies and a direct sales model.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.